CollPlant Biotechnologies Ltd (CLGN) stock
Close on Nov 11, 2026Market cap $5.72MP/E –Yield –
CollPlant Biotechnologies Ltd grew revenue 360.4% to $2.37M over fiscal 2025. Free cash flow was -$9.45M. At the latest close the market valued the company at $5.72M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $5.72M
- P/E ratio
- –
- Price to sales
- 2.41
- Price to book
- 1.94
- Dividend yield
- –
- Free cash flow yield
- -165.17%
Fundamentals
- Revenue
- $2.37M
- Net income
- -$11.49M
- EPS, diluted
- -$9.40
- Free cash flow
- -$9.45M
Trading
- Previous close
- $3.90
- Open
- $4.03
- Day's range
- $3.86 – $4.20
- Volume
- 25,053
- Average volume (20 days)
- 38,020
- Beta (5 years)
- 0.44
- 52-week range
- $2.64 – $22.50
- RSI (14 days)
- 50.8
- Volatility (1 year)
- 115.7%
- Relative volume
- 0.09×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLGN | S&P 500 | Difference | CLGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.8% | -2.4% | +15.2 pts | ||
| 3 months | +34.2% | -1.2% | +35.4 pts | ||
| Year to date | -71.7% | +12.3% | −84.0 pts | ||
| 1 year | -79.2% | +12.4% | −91.6 pts | ||
| 3 years | -93.0% | +78.8% | −171.8 pts | -58.7% | +21.4% |
| 5 years | -98.1% | +75.2% | −173.3 pts | -54.9% | +11.9% |
| 10 years | -96.7% | +311.1% | −407.8 pts | -28.9% | +15.2% |
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CollPlant Biotechnologies filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About CollPlant Biotechnologies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on medical aesthetics and the 3D bioprinting of tissues and organs. The company develops products based on recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants using proprietary technology. These offerings address indications in tissue repair and aesthetic medicine, encompassing bioinks, dermal and soft tissue fillers, and 3D-bioprinted tissues such as breast implants. CollPlant collaborates with pharmaceutical companies, including Allergan, an AbbVie company, and serves physicians, patients, third-party payors, and the broader medical community.
Company profile, executives and historyCollPlant Biotechnologies stock: common questions
What is CollPlant Biotechnologies's stock price?
CLGN closed at $3.96 on Nov 11, 2026, up 1.41% on the day. Over the past 52 weeks it traded between $2.64 and $22.50.
What is CollPlant Biotechnologies's market cap?
CollPlant Biotechnologies was worth $5.72M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CLGN's P/E ratio?
CollPlant Biotechnologies lost money over fiscal 2025 (diluted EPS -$9.40), so it has no meaningful P/E ratio.
How much revenue does CollPlant Biotechnologies make?
CollPlant Biotechnologies reported revenue of $2.37M for fiscal 2025, up 360.4% from a year earlier.
Does CollPlant Biotechnologies pay a dividend?
No. CollPlant Biotechnologies has not paid a cash dividend over the last twelve months.
How has CLGN stock performed over the past year?
Including dividends, CLGN returned -79.2% over the past year, against +12.4% for the S&P 500.
Who are CollPlant Biotechnologies's competitors?
Companies most similar to CollPlant Biotechnologies by business, industry and size include AVR, FEED, NTRB, HRGN, OSRH.
See a number that looks wrong?